You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK (GenomeWeb) – Myriad RBM announced today that it has signed an agreement to help Sanofi measure cardiovascular risk biomarkers in the blood samples of patients in a Phase III trial of its type II diabetes therapy lixisenatide.
...and receive Daily News bulletins.
Already have a 360Dx or GenomeWeb account?Login Now.
Don't have a 360Dx or GenomeWeb account?Register for Free.